Back to catalogue
№ 020 28 filings · 2021-09-03 → 2026-04-28

ARECOR THERAPEUTICS PLC

AREC
Health Care Market cap £25m Overall fit 150 /1000

Poor fit: not an AI beneficiary (formulation chemistry, not AI/data), binary clinical-stage rather than continuous operating leverage, and going-concern flag undermines downside protection. Valuation fair-to-mildly-undervalued but the strategy's three core pillars are largely absent.

Fair value range 55p–105p Mid case · £30m
Absolute upside +20.4% vs current market cap
Conviction 2/5 confidence in fair call
Supports the call
  • Sequel & Ligand deals provide observable third-party validation of AT278 and legacy IP economics
  • Clean balance sheet (net cash, no debt) and transparent disclosure of cash runway
  • Phase 1 AT278 data clinically de-risks the lead asset's PK/PD profile
Limits the call
  • Binary Phase 2/3 outcome and dependency on conversion of Sequel deal to commercialisation partnership
  • Going-concern material uncertainty; further raise needed before Phase 2
Methodology

Sum-of-parts / risk-adjusted NAV (cash + rNPV AT278 + platform optionality)

In one line · bull case

AT278 is a credibly de-risked, partner-validated ultra-concentrated insulin targeting a $3bn US opportunity, available at a market cap close to cash plus reasonable AT278 option value.

In one line · biggest risk

Phase 2 cannot start without further dilutive funding and a broader Sequel commercialisation deal that has not yet been signed — failure on either front would impair both AT278 economics and shareholder dilution.

Drivers
AI beneficiary 8 /100
Formulation/protein-stability technology; no AI exposure, no AI-driven revenue line.
Operating leverage 55 /100
High theoretical leverage on royalty/licence revenue against ~£6m fixed cost base, but only realised on successful clinical/regulatory outcome.
Earnings vs expectations 40 /100
Clinical milestones broadly on time; commercial/Tetris targets repeatedly missed, leading to subsidiary shutdown.
Growth momentum 35 /100
Continuing revenue roughly flat; Tetris discontinued; near-term inflexion depends on Sequel partnership conversion and Phase 2 start.
Moat 45 /100
100+ granted patents and a partner-validated formulation platform, but moat depends on AT278 clinical superiority being upheld.
Earnings quality 45 /100
Clean IFRS accounts but headline 2025 profit driven by one-off Ligand gain; going-concern material uncertainty disclosed.
Management quality 45 /100
Strategic refocus is sensible; but Tetris acquisition was fully impaired within two years, denting capital-allocation track record.
Cyclicality 15 /100
Diabetes therapeutics — non-cyclical demand.
Leverage 15 /100
Net cash, debt-free, but cash runway limited to May 2027 absent further raise.
Value-trap signals · 5
  • Going-concern material uncertainty disclosed in 2024 and 2025 audit reports
  • Repeated equity issuance with declining share price (300p+ in 2022 to ~66p today)
  • £3.3m Tetris Pharma impairment in 2024 and subsidiary shutdown in 2025
  • Recurring AT220 royalty stream sold to Ligand, leaving residual business more concentrated in higher-risk AT278
  • Further capital raise required before Phase 2 study can commence

ARECOR THERAPEUTICS PLC (AREC) — Investment research note

Executive summary

Arecor is a clinical-stage UK biotech developing AT278, an ultra-concentrated (500 U/mL) ultra-rapid-acting insulin designed to enable next-generation insulin pumps, alongside an oral GLP-1 peptide delivery platform. Across the period covered, the company refocused: it shut down loss-making subsidiary Tetris Pharma (announced Jan 2025), monetised legacy royalties via a $11m Ligand deal (Sep 2025), and signed a Phase-2-enabling co-development with US pump-maker Sequel Med Tech; cash rose modestly to £6.1m at YE25 2026-04 final results. The single most important valuation question is whether Sequel converts the initial $1.3m-each Phase-2-enabling deal into a broader commercialisation partnership for AT278 — without it, AT278 needs further dilutive funding before its planned 2H 2026 Phase 2 study.

Fair value estimate

Range: 55p – 105p per share (implied market cap range: £21m – £40m). Midpoint ~80p / £30m.

Methodology: sum-of-parts / risk-adjusted NAV.

  • Net cash & receivables: £6.1m cash + £0.7m deferred Ligand consideration + £0.5m further Ligand milestone expected 2026 ≈ £7.3m ≈ 19p/sh 2026-04 final results.
  • AT278 risk-adjusted value: Arecor cites ~2m US patient addressable population at >$3bn p.a. addressable 2026-04 final results. Assuming ~5% peak penetration, $150m peak sales to AT278 economics, ~10–15% royalty equivalent to Arecor under an eventual licence, ~25–30% probability of getting from current "Phase-2-enabling" stage through Phase 3 and to market, and 12% discount rate to a launch ~2031: NPV ≈ £15–30m ≈ 40–80p/sh.
  • Oral peptide / Arestat residual / future partnership pipeline: highly speculative optionality. £3–8m ≈ 8–20p/sh.
  • Less: funding gap pre-launch (cash runway to May 2027 only 2026-04 final results); Sequel partnership has not yet converted to commercialisation deal.

Vs. current £24.9m market cap (~66p): midpoint implies ~21% upside; range spans -17% downside to +59% upside. View: marginally undervalued / fair.

Sector context

  • Sector: Health Care / Pharmaceuticals & Biotechnology — confirmed.
  • Quality/growth/leverage vs. peers: Quality below sector average (going-concern material uncertainty disclosed in 2025 audit 2026-04 final results); growth profile binary and pre-revenue at scale; balance-sheet leverage low (net cash, no debt).
  • Listed peers: Other small UK/EU drug-delivery/formulation plays — Midatech Pharma, Diurnal (historic), Skinbiotherapeutics for AIM small-cap drug-platform comparators; Xeris Biopharma (US) is the most direct comparator for the insulin/ready-to-use franchise model.

Investment thesis (bull case)

  • AT278 has been clinically de-risked and partnered with a credible pump-maker. Sequel committed up to $1.3m alongside Arecor's $1.3m to Phase-2-enabling work, and "both companies have confirmed their strategic intent to enter a broader, co-development and commercialisation partnership" 2026-04 final results. ADA 2026 guidelines now endorse AID as preferred over MDI, expanding the addressable market AT278 specifically addresses — patients on >100 U/day cannot fill 3-day pumps with 100 U/mL insulin 2026-04 final results.
  • Non-dilutive Ligand royalty deal strengthens the balance sheet and validates legacy IP. $7m upfront received, $1m further milestones expected in 2026 — this funded AT278 work without share issuance 2025-09 interim.
  • Optionality from oral GLP-1 peptide platform at near-zero cost. Rybelsus® generated $3.4bn at <1% bioavailability; Arecor has positive in-vitro data, a new EPO patent filing for novel compositions, and a Scientific Advisory Board of leading oral-delivery experts — non-clinical PK data due during 2026 2026-04 final results.

Key risks

  • Going concern material uncertainty. Auditor flagged this; base-case cash runway to May 2027 only, and Phase 2 itself "will require further funding which we are already exploring" 2026-04 final results. The Phase 2 trigger is "contingent upon FDA approval and additional funding" — failure to raise on acceptable terms is the single biggest risk to shareholders.
  • Binary clinical outcomes and execution dependency on a single partner. Sequel is currently the only AT278 development partner; if the broader commercialisation deal does not materialise on favourable terms, AT278's value capture is materially impaired. Phase 2 hasn't started; only Phase 1 PK/PD data exists 2025-09 interim, 2026-04 final results.
  • Track record of writedowns and missed targets at subsidiaries. Tetris Pharma — acquired in Aug 2022 for £2.0m share consideration plus up to £4m earn-outs — was fully impaired (£3.3m exceptional in 2024) and shut down in 2025; neither earn-out target was achieved 2025-04 final results 2024, 2022-08 acquisition. Capital allocation history is mixed.

Operating leverage

The business model is a high-leverage royalty/platform model in theory: ongoing operating costs (~£5.9m total opex 2025: £2.7m R&D + £3.2m G&A 2026-04 final results) are largely fixed, and incremental royalty/milestone revenue would drop to near-100% contribution margin. Group revenue at £1.7m continuing (2025) is below break-even by ~£4–5m. The structure means a single successful licence/royalty (e.g. AT278 commercialisation, or oral-GLP-1 partner deal) could deliver multiples of current revenue at minimal incremental cost — Ligand's £5.0m one-off gain illustrates the magnitude possible from a single transaction 2026-04 final results. However, this leverage is only realised conditional on a successful clinical/regulatory outcome, which is multi-year and binary. There is no operating-leverage tailwind to AI demand here; revenue inflexion depends on partnership milestones and clinical readouts, not capacity utilisation.

Value-trap signals

  • Going-concern material uncertainty disclosed in both 2024 and 2025 audit reports 2026-04 final results, 2025-04 final results 2024.
  • Repeated equity issuance: £6.4m placing Aug 2024 at 90p 2024-07 placing; £6.0m placing Aug 2022 at 300p; cumulative dilution + price decline from 300p+ at IPO/2022 to ~66p today.
  • £3.3m impairment of Tetris Pharma in 2024; full subsidiary shutdown 2025.
  • AT220 royalty stream sold to Ligand — recurring revenue has been monetised, leaving the residual business more concentrated in higher-risk AT278.
  • Cash runway to May 2027 with further raise needed for Phase 2 — typical small-cap-biotech financing overhang.

Earnings vs. expectations

  • 2024: Tetris Pharma sales delayed by foil-pouch packaging issue (Sep 2024) 2024-09 interim; Board "continues to target consensus" but with caveats. FY 2024 revenue £5.1m vs prior £4.6m — close to in-line on the headline but materially below the bull case implied at the 2022 acquisition (Tetris target was "mid-single-digit million-pound net sales" in year 1 — earn-out NOT triggered) 2023-09 interim.
  • 2025 interim: Revenue £2.0m flat vs 1H 2024 2025-09 interim.
  • 2025 full year: Continuing revenue £1.7m (vs £1.6m 2024) — broadly in line on the continuing business; the headline FY profit of £1.0m was driven entirely by the £5.0m one-off Ligand royalty gain 2026-04 final results.
  • Pattern: clinical milestones (AT247, AT278 Phase 1 readouts; FDA Type C; Sequel deal) have largely been delivered on or close to time; commercial/Tetris targets were materially missed. Mixed but not a chronic "warner".

Conviction

Conviction: 2 (low).

  • Anchored by: clean disclosure, debt-free balance sheet, observable partnership economics (Sequel $1.3m commitment, Ligand $11m monetisation, comparable Xeris/Gvoke US uptake data).
  • Limited by: binary AT278 clinical/regulatory outcome, dependency on as-yet-unsigned broader Sequel commercialisation deal, going-concern material uncertainty, no DCF possible from current cash-burn business — valuation is essentially an option-value calculation with wide error bars.

Driver scoring & fit

This stock is a poor fit for the investor profile: it is not an AI beneficiary in any meaningful sense (formulation chemistry, not AI/data), its operating leverage is binary/clinical rather than continuous, and the going-concern flag breaches the "acceptable downside protection" requirement. The valuation looks fair to mildly undervalued, but the AI-receiver pillar — the single largest weight — is essentially absent.

Filings consulted · 30

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-04-28Posting OF Annual Report And Notice OF Agmm2026-04-28_9542512_posting-of-annual-report-and-notice-of-agmm.md0.95
  2. 2026-04-13Final Results2026-04-13_9515693_final-results.md1.00
  3. 2025-09-25Interim Results For The Six Months TO 30 June 20252025-09-25_9130272_interim-results-for-the-six-months-to-30-june-2025.md0.77
  4. 2025-09-24Notice OF Interim Results2025-09-24_9128515_notice-of-interim-results.md0.77
  5. 2025-06-02Result OF Agm2025-06-02_8908059_result-of-agm.md0.26
  6. 2025-05-06Posting OF 2024 Annual Report And Notice OF Agm2025-05-06_8863720_posting-of-2024-annual-report-and-notice-of-agm.md0.62
  7. 2025-04-22Final Results For 20242025-04-22_8838273_final-results-for-2024.md0.65
  8. 2025-02-03Arecor Full Year 2024 Trading Update2025-02-03_8717170_arecor-full-year-2024-trading-update.md0.55
  9. 2024-09-26Interim Results For Six Months Ended 30 June 20242024-09-26_8440216_interim-results-for-six-months-ended-30-june-2024.md0.58
  10. 2024-07-19Result OF Placing And Subscription2024-07-19_8321844_result-of-placing-and-subscription.md0.46
  11. 2024-07-19Proposed Placing And Subscription2024-07-19_8321022_proposed-placing-and-subscription.md0.46
  12. 2024-06-28Result OF Agm2024-06-28_8285425_result-of-agm.md0.20
  13. 2024-05-31Posting OF 2023 Annual Report And Notice OF Agm2024-05-31_8235351_posting-of-2023-annual-report-and-notice-of-agm.md0.62
  14. 2024-05-16Final Results For 20232024-05-16_8200119_final-results-for-2023.md0.45
  15. 2024-02-01Year End Trading Update2024-02-01_8016219_year-end-trading-update.md0.38
  16. 2023-09-14Interim Results For Six Months Ended 30 June 20232023-09-14_7754359_interim-results-for-six-months-ended-30-june-2023.md0.41
  17. 2023-08-10Notice OF Interim Results2023-08-10_7687266_notice-of-interim-results.md0.41
  18. 2023-06-09Result OF Agm2023-06-09_7568676_result-of-agm.md0.14
  19. 2023-06-09Agm Statement2023-06-09_7567241_agm-statement.md0.18
  20. 2023-05-04Arecor 2022 Annual Report And Notice OF Agm2023-05-04_7513838_arecor-2022-annual-report-and-notice-of-agm.md0.24
  21. 2022-09-08Interim Results For Six Months Ended 30 June 20222022-09-08_7269419_interim-results-for-six-months-ended-30-june-2022.md0.23
  22. 2022-08-17Notice OF Interim Results2022-08-17_7127774_notice-of-interim-results.md0.23
  23. 2022-08-01Result OF Placing2022-08-01_6956353_result-of-placing.md0.17
  24. 2022-08-01Proposed Acquisition OF Tetris Pharma Ltd2022-08-01_6954493_proposed-acquisition-of-tetris-pharma-ltd.md0.19
  25. 2022-05-23Result OF Agm2022-05-23_6974538_result-of-agm.md0.07
  26. 2022-05-23Arecor Agm Statement2022-05-23_6972874_arecor-agm-statement.md0.10
  27. 2022-04-27Arecor 2021 Annual Report And Notice OF Agm2022-04-27_7087436_arecor-2021-annual-report-and-notice-of-agm.md0.24
  28. 2022-04-25Final Results For The Year Ended 31 December 20212022-04-25_7039591_final-results-for-the-year-ended-31-december-2021.md0.25
  29. 2021-09-23Interim Results For Six Months Ended 30 June 20212021-09-23_6557512_interim-results-for-six-months-ended-30-june-2021.md0.23
  30. 2021-09-03Notice OF Interim Results2021-09-03_6718145_notice-of-interim-results.md0.23

This research note was authored by a large language model after reading 28 regulatory filings published between 2021-09-03 and 2026-04-28. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.